Collectively, these insights support the concept that HPV status, TP53 alterations, and LOY, together with immunological markers such as IL-12, interact to shape the tumour microenvironment and may ultimately influence immune responsiveness and clinical outcomes. Here, TP53 is linked to neoplasm.